Enzo Biochem Story

<div class='circular--portrait' style='background:#FF0000;color: #F8F8FF;font-size:4em;'>EB</div>
ENZ -- USA Stock  

USD 3.16  0.09  2.77%

Enzo Biochem Accounts Payable Turnover is fairly stable at the moment as compared to the past year. Enzo Biochem reported Accounts Payable Turnover of 11.06 in 2020. Accrued Expenses Turnover is likely to rise to 10.27 in 2021, whereas Net Income Per Employee is likely to drop (58.6 K) in 2021. The basic goal of this article is to give investors our perspective on Enzo Biochem for April. We will forecast Enzo Biochem value for investors.
Published over a month ago
View all stories for Enzo Biochem | View All Stories
Are Enzo Biochem (NYSE:ENZ) investors starting to hold back?
Over 62.0% of Enzo Biochem shares are held by institutions such as insurance companies. Institutional ownership of Enzo Biochem refers to the amount of Enzo Biochem equity owned by mutual funds, pension funds, insurance companies, investment firms, foundations, or other large entities that manage money on behalf of others. Check out our latest analysis of Enzo Biochem, including its current ownership diagnostics.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Enzo Biochem. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Enzo Biochem

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Enzo Biochem's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Enzo Biochem in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Enzo Biochem. Your research has to be compared to or analyzed against Enzo Biochem's peers to derive any actionable benefits. When done correctly, Enzo Biochem's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Enzo Biochem.

How important is Enzo Biochem's Liquidity

Enzo Biochem financial leverage refers to using borrowed capital as a funding source to finance Enzo Biochem ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Enzo Biochem financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Enzo Biochem's total debt and its cash.

How Enzo Biochem utilizes its cash?

To perform a cash flow analysis of Enzo Biochem, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Enzo Biochem is receiving and how much cash it distributes out in a given period. The Enzo Biochem cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Enzo Biochem Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Enzo Biochem reported Net Cash Flow from Operations of (19.76 Million) in 2020

Sale by Harbert Management Corp of 100000 shares of Enzo Biochem

Legal trades by Enzo Biochem insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Enzo Biochem insider trading alert for sale of common stock by Harbert Management Corp, the corporate stakeholder, on 17th of March 2021. This event was filed by Enzo Biochem Inc with SEC on 2021-03-17. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking it down a bit more

Enzo Biochem shows above-average downside volatility for the selected time horizon. We advise investors to inspect Enzo Biochem further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Enzo Biochem future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Enzo Biochem's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Enzo Biochem's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Returns Breakdown

Return on Investment(34.95)
Return on Assets(0.28)
Return on Equity(0.5)
Return Capital(0.59)
Return on Sales(0.45)

Will Enzo Biochem growth be justifiable after the rise?

Current Information Ratio is up to 0.06. Price may slide again. Enzo Biochem shows above-average downside volatility for the selected time horizon. We advise investors to inspect Enzo Biochem further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Enzo Biochem future alpha. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Enzo Biochem's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Enzo Biochem's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Take On Enzo Biochem

While other companies within the diagnostics & research industry are still a little expensive, even after the recent corrections, Enzo Biochem may offer a potential longer-term growth to investors. With an impartial outlook on the current market volatility, it may be better to hold off any inventment activity and neither purchase nor trade any shares of Enzo Biochem at this time. The Enzo Biochem risk-reward trade off is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Enzo Biochem.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Enzo Biochem. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com